How does 40M's PS Ratio compare to its peers?

40M is expensive based on its Price-To-Sales Ratio (4x) compared to the peer average (2.2x).

How does 40M's PS Ratio compare vs other companies in the DE Medical Equipment Industry?

40M is expensive based on its Price-To-Sales Ratio (4x) compared to the European Medical Equipment industry average (3.4x).

What is 40M's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

40M is expensive based on its Price-To-Sales Ratio (4x) compared to the estimated Fair Price-To-Sales Ratio (0x).

What is the Fair Price of 40M when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate 40M's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

Nanexa (DB:40M) - Stock Price, News & Analysis

40M Stock Overview

Operates as a nanotechnology drug delivery company. More details

40M fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Risk Analysis

Shareholders have been substantially diluted in the past year

Earnings are forecast to decline by an average of 4% per year for the next 3 years

Has less than 1 year of cash runway

Highly volatile share price over the past 3 months compared to the German market

+ 3 more risks

Nanexa AB (publ) Competitors

Geratherm Medical

XTRA:GME

€21.0m

aap Implantate

XTRA:AAQ1

€22.4m

Audientes

DB:AUG

€6.9m

PULSION Medical Systems

MUN:PUS

€134.4m

Price History & Performance

Summary of all time highs, changes and price drops for Nanexa
Historical stock prices
Current Share Price	SEK 0.086
52 Week High	SEK 0.15
52 Week Low	SEK 0.028
Beta	1.79
11 Month Change	-19.81%
3 Month Change	-34.25%
1 Year Change	66.28%
33 Year Change	-78.06%
5 Year Change	n/a
Change since IPO	-91.92%

Recent updates

Shareholder Returns

	40M	DE Medical Equipment	DE Market
7D	13.5%	2.4%	0.8%
1Y	66.3%	-5.0%	9.1%

Return vs Industry: 40M exceeded the German Medical Equipment industry which returned -6.8% over the past year.

Return vs Market: 40M exceeded the German Market which returned 8.5% over the past year.

Price Volatility

Is 40M's price volatile compared to industry and market?
40M volatility
40M Average Weekly Movement	16.7%
Medical Equipment Industry Average Movement	5.5%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.8%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: 40M's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: 40M's weekly volatility has decreased from 26% to 17% over the past year, but is still higher than 75% of German stocks.

About the Company

Founded	Employees	CEO	Website
2007	16	David Westberg	www.nanexa.com

Nanexa AB (publ) operates as a nanotechnology drug delivery company. It operates PharmaShell, a nanobased drug delivery platform that is an atomic layer deposition. The company also develops NEX-18, which drives the development of a PharmaShell that targets myelodysplastic Syndrome and Acute Myeloid Leukemia; NEX-20 for the treatment of multiple myeloma; and NEX-22 for the treatment of type 2 diabetes.

Nanexa AB (publ) Fundamentals Summary

How do Nanexa's earnings and revenue compare to its market cap?
40M fundamental statistics
Market cap	€17.70m
Earnings (TTM)	-€5.58m
Revenue (TTM)	€4.40m

4.0x

P/S Ratio

-3.2x

P/E Ratio

Is 40M overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
40M income statement (TTM)
Revenue	SEK 50.76m
Cost of Revenue	SEK 18.08m
Gross Profit	SEK 32.69m
Other Expenses	SEK 97.11m
Earnings	-SEK 64.42m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Feb 19, 2025

Earnings per share (EPS)	-0.47
Gross Margin	64.39%
Net Profit Margin	-126.91%
Debt/Equity Ratio	1.5%

How did 40M perform over the long term?

See historical performance and comparison

40M Stock Overview

Risk Analysis

Nanexa AB (publ) Competitors

XTRA:GME

€21.0m

XTRA:AAQ1

€22.4m

DB:AUG

€6.9m

MUN:PUS

€134.4m

Price History & Performance

Recent News & Updates

Nanexa AB Announces Positive Results in the Phase I Study for NEX-22, Long Acting GLP-1, in Type 2 Diabetes

Third quarter 2024 earnings released: kr0.03 loss per share (vs kr0.11 loss in 3Q 2023)

Nanexa AB (Publ) Completes Phase I Trial of NEX-22 in Type 2 Diabetes

New minor risk - Revenue size

Nanexa AB (Publ) Announces That the First Patient in the Third Dose Group with Their Long-Acting Depot Formulation of the Glp-1 Analog Liraglutide Has Been Dosed

New minor risk - Profitability

Recent updates

Nanexa AB Announces Positive Results in the Phase I Study for NEX-22, Long Acting GLP-1, in Type 2 Diabetes

Third quarter 2024 earnings released: kr0.03 loss per share (vs kr0.11 loss in 3Q 2023)

Nanexa AB (Publ) Completes Phase I Trial of NEX-22 in Type 2 Diabetes

New minor risk - Revenue size

Nanexa AB (Publ) Announces That the First Patient in the Third Dose Group with Their Long-Acting Depot Formulation of the Glp-1 Analog Liraglutide Has Been Dosed

New minor risk - Profitability

Second quarter 2024 earnings released: kr0.04 loss per share (vs kr0.16 loss in 2Q 2023)

Nanexa's Phase I Trial of NEX-22 in Type 2- Diabetes Progresses with Next Dose Group According to Plan

Nanexa AB (publ) Announces Chief Financial Officer Changes

Nanexa AB (Publ) Announces That First Patient Dosed in Nanexa's Phase I Trial of NEX-22 in Type 2 Diabetes

New major risk - Financial position

Nanexa AB Receives Approval for NEX-22 Clinical Study

Nanexa AB (publ) Elects Hanna Tilus as Members of the Board

First quarter 2024 earnings released: kr0.02 loss per share (vs kr0.14 loss in 1Q 2023)

Nanexa AB (publ) Announces Approval of Clinical Trial Application for NEX-22 Study Delayed

New major risk - Shareholder dilution

Full year 2023 earnings released: kr1.09 loss per share (vs kr1.16 loss in FY 2022)

Nanexa AB (publ), Annual General Meeting, May 15, 2024

Nanexa AB Announces Clinical Trial Application for NEX-22 Phase I Study Assess by EMA

Third quarter 2023 earnings released: kr0.11 loss per share (vs kr0.24 loss in 3Q 2022)

Nanexa AB Completes Clinical Phase I Study with NEX-20

Second quarter 2023 earnings released: kr0.16 loss per share (vs kr0.32 loss in 2Q 2022)

Second quarter 2023 earnings released: kr0.16 loss per share (vs kr0.32 loss in 2Q 2022)

Nanexa AB Confirms Continued Positive Results from A New Preclinical Study of Nex-22

Nanexa AB (Publ) Approves Election of Jakob Dynnes Hansen as Member of the Board

Nanexa AB (Publ) Announces Urban Paulsson and Bengt Gustavsson Declines Re-Election

First quarter 2023 earnings released: kr0.14 loss per share (vs kr0.24 loss in 1Q 2022)

Nanexa AB (publ) to Report Q1, 2023 Results on May 04, 2023

Full year 2022 earnings released: kr1.16 loss per share (vs kr1.01 loss in FY 2021)

Nanexa AB (publ) to Report Q4, 2022 Results on Feb 16, 2023

Nanexa Starts the Phase 1 Study of NEX-20 According to Plan

No longer forecast to breakeven

Nanexa Receives Approval to Start Clinical Trial with NEX-20

Third quarter 2022 earnings released: kr0.24 loss per share (vs kr0.18 loss in 3Q 2021)

Nanexa AB (Publ) and Vitrivax, Inc Reach Agreement in Principle

Nanexa AB (Publ) Launches NEX-22 Product Project to Address Huge Market

Second quarter 2022 earnings released: kr0.32 loss per share (vs kr0.33 loss in 2Q 2021)

Nanexa AB (publ) to Report Nine Months, 2022 Results on Oct 25, 2022

Nanexa AB (publ) Receives Extended GMP-Certificate for the New Pilot Plant

Less than half of directors are independent

Nanexa AB (publ), Annual General Meeting, Jun 09, 2022

Nanexa Receives Grant from VINNOVA for Study with Monoclonal Antibodies

Forecast to breakeven in 2023

First quarter 2022 earnings released: kr0.24 loss per share (vs kr0.29 loss in 1Q 2021)

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Nanexa AB Announces That the Company's Preclinical Investigation

High number of new directors

Nanexa Announces Inclusion of Patients in its Phase I Study with NEX-18

Second quarter 2021 earnings released

Forecast to breakeven in 2023

High number of new directors

First quarter 2021 earnings released: kr0.29 loss per share (vs kr0.22 loss in 1Q 2020)

Nanexa Appoints Jonas Fransson as Head of Pharmaceutical Development

Full year 2020 earnings released: kr1.09 loss per share (vs kr0.88 loss in FY 2019)

Nanexa AB to Report Q1, 2021 Results on May 06, 2021

Shareholder Returns

Price Volatility

About the Company

Nanexa AB (publ) Fundamentals Summary

4.0x